In this study, we discovered a high-affinity human anti-CD99 antibody, NOA2, capable of binding Ewing sarcoma cells, and subsequently explored the in vitro and in vivo activity of this antibody to engage macrophages, impact tumor growth, and modulate macrophage function. This evidence concerns the gene CD99 and Ewing sarcoma.